Baker Bros. Adds $58.6M Kodiak Sciences Stake After Phase 3 Win
KOD has more than doubled off its 52-week low of $10.94 on elevated volume (3.4× avg).
Summary
Baker Bros. Advisors LP and affiliates purchased $58.6 million of Kodiak Sciences stock on the day the company reported positive Phase 3 results for two lead drug candidates.
Key Events · Ownership and Investor Activity · KOD
-
Baker Bros. Buys $58.6M of KOD
Baker Bros. Advisors LP and affiliated funds acquired 807,840 shares for $58,625,708 on 2026-09-28 at prices ranging from $61.21 to $78.57.
-
Purchase Follows Positive Phase 3 Data
The purchase occurred the same day Kodiak announced Zenkuda and tabirafusp-ted met primary endpoints in the DAYBREAK trial, driving the stock up sharply.
-
Stake Rises to 19.1M Shares
Post-transaction holdings total 19,121,134 shares across the reporting entities, with Felix J. Baker serving as a director of the company.
-
Sophisticated Investor Confidence
Baker Bros. is a prominent life-sciences investment firm with board representation; the size and timing of the purchase signal strong conviction in the company's clinical and commercial outlook.
Analysis · KOD · Life Sciences
A $58.6 million purchase of Kodiak Sciences stock by Baker Bros. Advisors LP and affiliated funds on September 28 underscores the significance of the company's Phase 3 results. That same day, Kodiak announced that both Zenkuda and tabirafusp-ted met primary endpoints in the pivotal DAYBREAK trial. The 807,840 shares were acquired at prices between $61.21 and $78.57, well above pre-announcement levels, bringing the group's total holdings to 19.1 million shares. This is a large, real-money commitment from a sophisticated life-sciences investor with board representation, made immediately after positive data — a strong vote of confidence in the company's commercial prospects.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KOD was trading at $94.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $10.94 to $98.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.